Mesoblast Limited (MESO) Stock Analysis & Winston Score

Mesoblast is an Australian biotechnology company that develops cell-based medicines to treat serious diseases. Its main product is Ryoncil (remestemcel-L), a therapy made from special cells called mesenchymal stem cells that help calm dangerous inflammation in the body. The company focuses on conditions like steroid-refractory acute graft versus host disease (aGvHD), a life-threatening complication that can occur after bone marrow transplants, primarily in children. Mesoblast earns revenue through product sales and licensing deals with pharmaceutical partners, though it is not yet consistently profitable and spends heavily on clinical trials and research. The company operates globally, with roots in Australia and commercial activity in the United States, where Ryoncil received FDA approval in 2024 for pediatric aGvHD. Its main competitive edge is its proprietary cell therapy platform, which is difficult and expensive to replicate. The key growth driver is expanding Ryoncil's commercial uptake and advancing its pipeline into additional inflammatory and cardiac conditions, while the main risk remains the high cost of scaling cell therapy manufacturing.